Special Issue "Anticancer Agents: Design, Synthesis and Evaluation"
Deadline for manuscript submissions: 31 March 2020
Assoc. Prof. Dr. Qiao-Hong Chen
Department of Chemistry, California State University, Fresno 2555 E. San Ramon Ave. M/S SB70 Fresno, CA 93740, USA
Website | E-Mail
Interests: anticancer agents; medicinal chemistry; natural products; bioorganic chemistry; organic synthesis; drug design and synthesis; prostate cancer; lead compound optimization; biological evaluation
The currently available cancer therapies still have various limitations, such as multi-drug resistance, undesired off-target effects, and unpredictable efficacies. The cancer-related mortality rate still remains high. The development of novel anticancer agents thus continues to be imperative to combat various deadly cancers. The emerging molecular targets and signal pathways enable the development of novel strategies for the rational design of new anticancer agents. Numerous well-established synthetic methods and biological screening assays have paved the way for the discovery and development of new anticancer agents. This Special Issue of Molecules is devoted to all aspects of recent studies searching for new anticancer agents. Both original research and review articles focusing on the rational design, synthesis, and/or biological evaluation of various agents (including small molecules, natural products, intrinsic molecules, antibodies and vaccines) as potential cancer therapeutics are welcome to be submitted for publication in this Special Issue.
Assoc. Prof. Dr. Qiao-Hong Chen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer drug discovery
- cancer drug development
- medicinal synthesis
- cancer therapy
- anticancer activity
- rational drug design
- Structure-activity relationship
- cancer therapeutics
- anticancer agent
- antitumor agent
- biological evaluation
- cancer bioassay
- cancer screening assay
- natural product
- small molecule enzyme inhibitor
- receptor antagonist
- lead optimization
- structure modification
- structure manipulation
- anti-proliferative activity
- cell apoptosis
- cancer cell models
- anti-tumor efficacy
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Enzalutamide and Its Analogs as Therapeutics for Castration-Resistant Prostate Cancer
Article Type: Review
Authors: Pravien Rajaram, Qiao-Hong Chen *
Abstract: Enzalutamide is a synthetic second-generation androgen receptor (AR) antagonist with a strong binding affinity to AR. Most importantly, enzalutamide can significantly prolong overall survival time for patients with lethal castration-resistant prostate cancer (CRPC). Enzalutamide has thus been approved by the US Food and Drug Administration for the treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC. This review will cover the rational design and development of enzalutamide, and will then describe its synthesis, medicinal chemistry, mechanisms of action, and pharmacokinetic profiles. The interaction of enzalutamide with other chemotherapeutics and the mechanisms of enzalutamide resistance will also be summarized.
Title: Itaconic-quinoline hybrids as potential anticancer agents
Article Type: Article
Author: Branka Zorc